StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.

The post StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day appeared first on GEN - Genetic Engineering and Biotechnology News.